Computational chemistry

Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

Retrieved on: 
Tuesday, April 16, 2024
University, Cancer, Organic chemistry, University of Pennsylvania, AI, Merck & Co., Johnson & Johnson, Data science, Najat, Doctor of Philosophy, Research, Artificial intelligence, Entrepreneurship, Science, Patient, Chemistry, Biology, Ethics, Colgate University, Drug discovery, Committee, Economics, Computational chemistry, Pharmaceutical industry

SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer.

Key Points: 
  • SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer.
  • Dr. Khan will lead Recursion’s research and development, and build its emerging commercial capabilities.
  • “Najat brings a unique blend of leadership in biological, chemical, and medical sciences, data science, and business,” said Chris Gibson, Co-Founder and CEO of Recursion.
  • Najat is the founder and co-chair of the Data Science in Industry Roundtable (DISRUPT) – a cross industry forum dedicated to driving impact through Data Science.

Odyssey Therapeutics Announces Strategic Collaboration to Advance AI-Driven Small Molecule Drug Discovery

Retrieved on: 
Thursday, April 4, 2024
Biotechnology, Health, Pharmaceutical, Technology, Artificial Intelligence, Odyssey, Johnson & Johnson, Drug discovery, Patient, Artificial intelligence, Computational chemistry, Therapy, Machine learning, Pharmaceutical industry

Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision medicines, announced today it has entered into a strategic research collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company, to jointly discover and optimize small molecule medicines against select therapeutic targets.

Key Points: 
  • Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision medicines, announced today it has entered into a strategic research collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company, to jointly discover and optimize small molecule medicines against select therapeutic targets.
  • The companies will combine their expertise in artificial intelligence (AI), machine learning (ML), computational chemistry and drug discovery to unlock difficult-to-drug targets.
  • “We are excited about this collaboration to push the boundaries of the drug discovery and development process, using the latest advancements in AI and ML to find solutions for serious diseases,” said Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics.
  • Odyssey will receive an upfront payment and is eligible for milestone payments and royalties.

X‑Chem Adds Chief Technology Officer to Bolster Its Digital Drug Discovery Strategy

Retrieved on: 
Tuesday, April 2, 2024
Software, Research, Pharmaceutical, Technology, Artificial Intelligence, Genetics, Health Technology, Clinical Trials, Science, Biotechnology, Other Science, Health, Machine learning, Informatics, Computational chemistry, Chem, Creativity, Drug discovery

X-Chem, the leading provider of innovative solutions in early-stage drug discovery, today announced the addition of Dr. Erin Davis as chief technology officer.

Key Points: 
  • X-Chem, the leading provider of innovative solutions in early-stage drug discovery, today announced the addition of Dr. Erin Davis as chief technology officer.
  • Dr. Davis brings extensive experience in the areas of data strategy, informatics, computational chemistry and software solutions in drug discovery.
  • The addition of Dr. Davis to X-Chem’s executive team bolsters X-Chem’s strategy of leveraging its data generation platforms and deploying digitized drug discovery solutions to its clients.
  • “I am so excited to see Erin join the amazing team we have here at X-Chem,” said Karen Lackey, chief executive officer.

Turbine and Harmonic Discovery Pair Simulation-Guided Biology and Multi-Target Kinase Inhibition Chemistry Expertise to Develop a Novel Cancer Therapy

Retrieved on: 
Monday, April 1, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Entrepreneurship, Drug discovery, Patient, NEK1, Biology, Computational chemistry, Harmonic, Therapy, Multimedia, Polypharmacology

Turbine, a company that is building the world’s first predictive simulation of patient biology, and Harmonic Discovery (Harmonic), a therapeutics company building an integrated computational and experimental platform for kinase drug discovery and targeted polypharmacology, have entered into a collaboration to co-develop novel cancer therapies that will inhibit a dark kinase identified for cancer dependency using Turbine’s Simulated Cell™ platform.

Key Points: 
  • Turbine, a company that is building the world’s first predictive simulation of patient biology, and Harmonic Discovery (Harmonic), a therapeutics company building an integrated computational and experimental platform for kinase drug discovery and targeted polypharmacology, have entered into a collaboration to co-develop novel cancer therapies that will inhibit a dark kinase identified for cancer dependency using Turbine’s Simulated Cell™ platform.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240401176466/en/
    “We believe that the dark kinase NEK1 holds great potential as a drug target for developing cancer therapies addressing important resistance challenges in the clinic,” said Daniel Veres, M.D., Ph.D., Chief Scientific Officer and Co-Founder of Turbine.
  • Harmonic will assume responsibilities for computational chemistry and medicinal chemistry activities, while Turbine will be responsible for in silico simulations and wet-lab validation of target biology, including the identification of both synergistic kinase co-targets to NEK1 and patient populations most likely to benefit from therapies.

Hokkaido University finds a new route to recyclable polymers from plants

Retrieved on: 
Thursday, March 21, 2024
Environment, Assistant, Recycling, Polymer, Research, ACS Macro Letters, Artificial intelligence, Hokkaido University, Plant, LGO, Computational chemistry, Plastic, Biomass

SAPPORO, Japan, March 21, 2024 /PRNewswire/ -- Researchers at Hokkaido University have taken a significant step forward in the drive to make recyclable yet stable plastics from plant materials. This is a key requirement to reduce the burden of plastic pollution in the environment. They developed a convenient and versatile method to make a variety of polymers from chemicals derived from plant cellulose; crucially, these polymers can be fully recycled. The method was published in the journal ACS Macro Letters.

Key Points: 
  • Cellulose, abundantly available from plant biomass, can be converted into molecules used to make a new class of recyclable polymers, to sustainably replace some plastics.
  • SAPPORO, Japan, March 21, 2024 /PRNewswire/ -- Researchers at Hokkaido University have taken a significant step forward in the drive to make recyclable yet stable plastics from plant materials.
  • They developed a convenient and versatile method to make a variety of polymers from chemicals derived from plant cellulose; crucially, these polymers can be fully recycled.
  • To make their new polymers, the Hokkaido team used two commercially available small molecules, levoglucosenone (LGO) and dihydrolevoglucosenone (Cyrene), which are made from cellulose.

Hokkaido University finds a new route to recyclable polymers from plants

Retrieved on: 
Thursday, March 21, 2024
Environment, Assistant, Recycling, Polymer, Research, ACS Macro Letters, Artificial intelligence, Hokkaido University, Plant, LGO, Computational chemistry, Plastic, Biomass

SAPPORO, Japan, March 21, 2024 /PRNewswire/ -- Researchers at Hokkaido University have taken a significant step forward in the drive to make recyclable yet stable plastics from plant materials. This is a key requirement to reduce the burden of plastic pollution in the environment. They developed a convenient and versatile method to make a variety of polymers from chemicals derived from plant cellulose; crucially, these polymers can be fully recycled. The method was published in the journal ACS Macro Letters.

Key Points: 
  • Cellulose, abundantly available from plant biomass, can be converted into molecules used to make a new class of recyclable polymers, to sustainably replace some plastics.
  • SAPPORO, Japan, March 21, 2024 /PRNewswire/ -- Researchers at Hokkaido University have taken a significant step forward in the drive to make recyclable yet stable plastics from plant materials.
  • They developed a convenient and versatile method to make a variety of polymers from chemicals derived from plant cellulose; crucially, these polymers can be fully recycled.
  • To make their new polymers, the Hokkaido team used two commercially available small molecules, levoglucosenone (LGO) and dihydrolevoglucosenone (Cyrene), which are made from cellulose.

Iktos opens a subsidiary in Japan and entrusts its management to Hideyoshi Fuji

Retrieved on: 
Wednesday, February 14, 2024
Molecule, Urology, Pharmacy, Doctor of Philosophy, AI, Yann, Saas, Generative, Drug design, Drug discovery, RIKEN, Kissei, Retrosynthetic analysis, Software as a service, Astellas Pharma, Artificial intelligence, Computational chemistry, Toyotomi Hideyoshi, Ono Pharmaceutical, Pharmaceutical industry

Paris (France) and Tokyo (Japan), February 14, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, announces the opening of Iktos K.K., its new subsidiary in Japan.

Key Points: 
  • Paris (France) and Tokyo (Japan), February 14, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, announces the opening of Iktos K.K., its new subsidiary in Japan.
  • Hideyoshi Fuji has been appointed Representative Director of Iktos K.K., and Vice-President, Japan Business Development and Operations.
  • Hideyoshi, 42, spent 13 years at Astellas Pharma Inc. (2009-2021) as an expert in computational chemistry and chemoinformatics.
  • After his career with Astellas Pharma, Hideyoshi became an entrepreneur in 2022 and supported business development and marketing efforts in Japan for overseas software companies.

PsiQuantum, Mitsubishi UFJ Financial Group and Mitsubishi Chemical Announce Partnership to Design Energy-Efficient Materials on PsiQuantum’s Fault-Tolerant Quantum Computer

Retrieved on: 
Wednesday, January 24, 2024
Semiconductor, Chemicals, Plastics, Technology, Manufacturing, Other Manufacturing, Hardware, Mitsubishi UFJ Financial Group, Physics, Mitsubishi Chemical Corporation, Chemistry, Partnership, Density functional theory, Density, DFT, Climate, Computational chemistry, MUFG, Mitsubishi Group

Mitsubishi UFJ Financial Group (MUFG) is committed to supporting the world’s transition to a sustainable future, and to encourage industry access to the most promising breakthrough technologies.

Key Points: 
  • Mitsubishi UFJ Financial Group (MUFG) is committed to supporting the world’s transition to a sustainable future, and to encourage industry access to the most promising breakthrough technologies.
  • By pioneering PsiQuantum’s Qlimate solutions with industry leader Mitsubishi Chemical, MUFG is at the forefront of quantum computing for sustainability.
  • The project will allow Mitsubishi Chemical to gain early insights into how and when fault-tolerant quantum computing can be deployed in support of critical, scalable, sustainable materials.
  • We hope the partnership will accelerate the innovation of revolutionizing computational studies in chemistry and materials science.”

Svante Charts the Course to a Greener Future, Fueling Innovation with Rescale

Retrieved on: 
Wednesday, January 17, 2024
CO2, FEA, Carbon, Climate change, Computational chemistry, DAC, Research, HPC, Renewable energy

"Working with Rescale has assisted in accelerating our innovation and bringing our vision for a sustainable future closer to reality."

Key Points: 
  • "Working with Rescale has assisted in accelerating our innovation and bringing our vision for a sustainable future closer to reality."
  • "We are proud to support Svante in its mission to combat climate change," said Joris Poort, CEO of Rescale.
  • From the stage in Davos, Svante and Rescale extend a call to action to businesses and global leaders.
  • Svante, with the power of the Rescale platform and other solutions, is paving the way for a greener future, and invites everyone to join the journey.

Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

Retrieved on: 
Tuesday, January 16, 2024
JPMorgan Chase, Amgen, Research, Mitsui & Co., Airbus, AI, HSBC, Carbon, Digital, Transport, Cambridge Quantum Computing, Organization, Computational chemistry, BMW, Cryptocurrency

CHARLOTTE, N.C., Jan. 16, 2024 /PRNewswire/ -- Honeywell (NASDAQ: HON) today announced the closing of a $300 million equity fundraise for Quantinuum, the world's leading integrated quantum computing company, at a pre-money valuation of $5 billion. The round is anchored by Quantinuum's strategic partner JPMorgan Chase, with additional participation from Mitsui & Co., Amgen and Honeywell, which remains the company's majority shareholder. This investment brings the total capital raised by Quantinuum since inception to approximately $625 million.

Key Points: 
  • CHARLOTTE, N.C., Jan. 16, 2024 /PRNewswire/ -- Honeywell (NASDAQ: HON) today announced the closing of a $300 million equity fundraise for Quantinuum, the world's leading integrated quantum computing company, at a pre-money valuation of $5 billion.
  • The round is anchored by Quantinuum's strategic partner JPMorgan Chase, with additional participation from Mitsui & Co., Amgen and Honeywell, which remains the company's majority shareholder.
  • This investment brings the total capital raised by Quantinuum since inception to approximately $625 million.
  • This capital raise represents Quantinuum's first equity funding round since Cambridge Quantum Computing and Honeywell Quantum Solutions merged in November 2021.